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Background: In vitro data indicate quercetin has anti-oxidative and anti-inflammatory functions with 
the potential to lower disease risk factors, but data in human beings are limited. 
Objective The objective of this study was to investigate the effect of quercetin, vitamin C, and niacin 
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samples were taken pre- and post-supplementation, and plasma quercetin, inflammatory markers (ie, C-
reactive protein and five cytokines), diagnostic blood chemistries, blood pressure, and blood lipid 
profiles were measured.  
Results Plasma quercetin increased in the Q-500 and Q-1,000 groups. No differences in blood 
chemistries were found except for a small decrease in serum creatinine and increase in glomerular 
filtration rate in Q-500 and Q- 1,000 groups. A small decrease in mean arterial blood  pressure was 
measured for Q-500 and Q-1,000 groups compared to placebo. A difference in serum total cholesterol 
was measured between Q-500 and placebo groups, and there was small decrease in high-density 
lipoprotein cholesterol levels in the Q-1,000 group. Change in inflammatory measures did not differ 
between groups except for a slight decrease in interleukin-6 for the Q-1,000 group. Conclusions Q-500 
or Q-1,000 supplementation for 12 weeks had a negligible influence on disease risk factors.
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ABSTRACT 
Background In vitro data indicate quercetin has anti-
oxidative and anti-inflammatory functions with the 
potential to lower disease risk factors, but data in 
human beings are limited. 
Objective The objective of this study was to investigate the 
effect of quercetin, vitamin C, and niacin supplements 
(500 mg quercetin, 125 mg vitamin C, and 5 mg niacin 
[Q-500]; 1,000 mg quercetin, 250 mg vitamin C, and 10 
pressure was measured for Q-500 and Q-1,000 groups 
compared to placebo. A difference in serum total 
cholesterol was measured between Q-500 and placebo 
groups, and there was small decrease in high-density 
lipoprotein cholesterol levels in the Q-1,000 group. 
Change in inflammatory measures did not differ between 
groups except for a slight decrease in interleukin-6 for 
the Q-1,000 group. Conclusions Q-500 or Q-1,000 
supplementation for 12 weeks had a negligible influence 
on disease risk factors. 
mg niacin [Q-1,000]), on disease risk factors in a large 
group of community adults (n=1,002, 60% women) vary- 
ing widely in age and body mass index. 
Design Subjects were randomized into one of three groups 
(placebo, Q-500, or Q-1,000) and ingested supplements for 
12 weeks. Blood samples were taken pre- and post-
supplementation, and plasma quercetin, inflammatory 
markers (ie, C-reactive protein and five cytokines), 
diagnostic blood chemistries, blood pressure, and blood 
lipid profiles were measured. 
Results Plasma quercetin increased in the Q-500 and 
Q-1,000 groups. No differences in blood chemistries were 
found except for a small decrease in serum creatinine and 
increase in glomerular filtration rate in Q-500 and Q-
1,000 groups. A small decrease in mean arterial blood 
lavonoids, a group of naturally occurring polypheno- 
lic compounds found in plants, are associated with
antioxidative (1), anti-inflammatory (2), antipatho- 
genic (3,4), cardioprotective (5), and anticarcinogenic (6) 
activities. Inflammation and oxidative stress are key 
mechanisms in the pathogenesis of certain disease states, 
supporting the strategy of increased flavonoid intake ei- 
ther through diet or supplementation for prevention of 
cardiovascular disease (CVD). Indeed, epidemiologic 
studies indicate that high consumption of foods rich in 
flavonoids is associated with a decrease in CVD risk fac- 
tors (7-9), and risk of CVD (5). Flavonoid supplementa- 
tion as a therapeutic method for reducing disease risk 
factors is receiving increasing attention. 
In vitro and animal studies support the notion that 
quercetin, the major flavonoid consumed by human be- 
ings, reduces disease risk factors (10). For example, in 
mice fed a high-fat diet, quercetin lowered circulating 
plasma cytokines (interferon-, interleukin [IL]-1, and 
IL-4), without a change in body composition or weight 
(11). In addition, quercetin significantly decreased serum 
total cholesterol and phospholipid levels, and liver en- 
zyme activity involved with fatty acid synthesis in mice 
fed quercetin for 15 days (12). In rats, quercetin inhibits 
nuclear factor-kappaB, cytokine expression, and cyto- 
kine-inducible nitric oxide synthase expression (13,14), 
and decreases blood pressure (15,16). 
Data on the effects of supplemental isolated flavonoids, 
specifically quercetin, on lowering disease risk factors in 
humans is limited with conflicting results (17). Egert and 
colleagues (18) reported no effect of 2 weeks of quercetin 
supplementation (50, 100, or 150 mg/day) on inflamma- 
tory markers, lipid profile, or body composition in 35 
healthy subjects. In a subsequent crossover trial of 93 
overweight subjects, Egert and colleagues (19) reported a 
decrease in both systolic blood pressure and high-density 
lipoprotein (HDL) cholesterol after 6 weeks of ingesting 
quercetin at a dose  of  150  mg/day. Conquer and col- 
leagues (20) reported no change in serum lipoproteins or 
blood pressure in 27 healthy subjects ingesting 1,000 
mg/day quercetin for 1 month. Another study found that 
730 mg quercetin/day for 1 month decreased blood 
pressure in overweight subjects with mild hypertension 
(21). Egert and colleagues (19) proposed that quercetin 
may provide protection against CVD, especially in 
those at high risk. 
Quercetin-related benefits on CVD risk factors are un- 
clear given inconsistencies in dosing regimens and low 
subject numbers in previous trials in human beings. Our 
study investigated two doses of quercetin combined with 
vitamin C and niacin (500 mg quercetin, 125 mg vitamin 
C, and 5 mg niacin [Q-500]) or 1,000 mg quercetin, 250 
mg vitamin C, and 10 mg niacin [Q-1,000], for 12 weeks 
on disease risk factors (eg, blood pressure, blood lipid 
levels, and inflammatory cytokines) in a large community 
group (n=1,002) varying widely in age and body mass 
index (BMI). Doses were based on prior studies of human 
beings conducted in our lab (22). The mixture was based 
on unpublished animal studies showing increased bio- 
availability of quercetin when mixed with vitamin C (1:1 
ratio) and niacin (Quercegen Pharma, personal 
communication, September 2006). Our hypothesis 
was that a quercetin-vitamin C-niacin supplement 
(Q-500 or Q-1000) would improve disease risk factors 
compared to placebo. 
METHODS 
Subjects 
Male and female noninstitutionalized subjects (N=1,023), 
18 to 85 years of age, were recruited via mass advertising 
from the community. Approximately half of subjects were 
studied during a 12-week period from January to April 
2008, and the second half from August to November 2008. 
Women who were pregnant or lactating were excluded from 
the study, but no other exclusion criteria were employed. 
Both diseased and non-diseased subjects were allowed 
to participate, and during recruitment, subjects were 
strati- fi    by sex (40% men), age (40% young adults aged 
18 to 40 years, 40% middle-aged adults aged 41 to 65, 
and 20% elderly adults, aged 65 and older), and BMI (45% 
normal or 
18.5 to 24.9, 30% overweight or 25 to 29.9, and 25% obese or 
2:30) to ensure representation of these various subgroups. 
Thirty-seven percent of subjects reported past or current 
history for one or more chronic diseases: hypertension 
(19%), arthritis (16%), cancer (6%), cardiovascular disease 
(4%), and/or diabetes (4%). Where noted, subjects taking 
medication for a chronic disease were excluded from 
analysis. During the study, subjects agreed to avoid any 
other supplements containing quercetin; no other 
restrictions were placed on diet, supplement use, or 
medications. All experimental procedures were approved 
by the Appalachian State University Institutional 
Review Board, and written informed consent was 
obtained from each subject. 
Research  Design 
Subjects were randomized to one of three groups: Q-500 
(500 mg quercetin, 125 mg vitamin C, 5 mg niacin/day), 
Q-1,000 (1,000 mg quercetin, 250 mg vitamin C, 10 mg 
niacin/day), or placebo. Supplements were administered 
utilizing double-blind procedures. Subjects ingested two 
soft chew supplements twice daily (upon awakening, and 
between 2 PM and the last meal of the day) during the 
12-week study period. Supplements were prepared by 
Nutravail Technologies (Chantilly, VA) with Quercegen 
Pharma (Newton, MA), and were soft, individually 
wrapped chews (5.3 g/piece) that contained either 125 or 
250 mg quercetin, 125 or 250 mg vitamin C (ascorbic acid 
and sodium ascorbate), 5 or 10 mg niacin, and 20 kcal 
sugars in a carnauba wax, soy lecithin, corn starch, glyc- 
erin, and palm oil base colored with FD&C Yellow No. 5 
and No. 6. Placebo supplements were prepared exactly 
the same way minus the quercetin, ascorbic acid and 
sodium ascorbate, and niacin. Data from Quercegen 
Pharma (unpublished data, personal communication, 
September 2006) indicate that the bioavailability of 
quercetin is enhanced with vitamin C and niacin, and 
thus this study tested whether the combination of 
quercetin, vitamin C, and niacin had an influence on 
the outcome measures. 
Following the first blood sample, subjects began 
supplementing with the chews and continued this for 
12 weeks. The following information was also reported 
via monthly logs by each subject: adherence to the 
supple- mentation regimen; physical activity and diet 
status; change in disease status and medication use; and 
gastro- intestinal (constipation, heartburn, bloating, 
diarrhea, nausea, and vomiting), skin (rash, dryness, and 
flushing), allergy, and mental (energy, headache, stress, 
and focus/ concentration) symptoms. 
Outcome  Measures 
To obtain lifestyle habit information, subjects were asked 
to complete a lifestyle habit survey 2 weeks before the 
first lab visit for the study. Height was measured using a 
stadiometer, whereas body mass and body composition 
were measured using a Tanita bioelectrical impedance 
scale (Tanita, Arlington Heights, IL). Following an over- 
night fast, and a 15-minute seated rest, resting blood 
pressure was measured. Blood samples were obtained 
following the overnight fast (between 7 and 9 AM) before 
and after the  12-week  supplementation period. These 
blood samples were then analyzed for outcome measures 
as described below. Unless otherwise specified all 
chemicals were purchased from Sigma Aldrich (St Louis, 
MO). 
Plasma Quercetin. Plasma quercetin was measured as pre- 
viously described (22). Briefly, total plasma quercetin 
(quercetin and its primary conjugates) from heparin- 
treated blood was measured following solid-phase extrac- 
tion via reversed-phase high-performance liquid chroma- 
tography with ultraviolet detection. Quercetin conjugates 
were hydrolyzed by incubating 500-L plasma aliquots 
with 10 L 10% DL-dithiothreitol solution, 50 L 0.58 mol/
L acetic acid, 50 L of a mixture of -glucuronidase/ 
arylsulfatase, and crude extract from Helix pomatia 
(Roche Diagnostics Corporation, Indianapolis, IN) for 2 
hours at 37°C. Chromatographic analysis was performed 
using the Ultimate 3000 HPLC-PDA system (Dionex 
Corporation, Sunnyvale, CA) with a Gemini C18 column 
(Phenomenex, Torrance, CA). 
Table 1. Subject characteristics (n=1,002) for placebo, Q-500a, and Q-1,000b groups 
Placebo (n=335; Q-500 (n=334; Q-1,000 (n=333; 
Variable 122 men, 213 women) 138 men, 196 women) 134 men, 199 women) 
Age (y) 
Men 43.8±1.6 45.3±1.5 45.5±1.4 
Women 47.4±1.1 47.2±1.1 45.2±1.1 
Weight (kg) 
Men 85.2±1.3 86.0±1.6 88.4±1.5 
Women 71.4±1.1 71.9±1.2 71.5±1.3 
Height (m) 
Men 1.77±0.01 1.78±0.01 1.77±0.01 
Women 1.64±0.01 1.65±0.01 1.64±0.01 
Body mass index 
Men 27.1±0.4 27.1±0.5 28.2±0.4 
Women 26.4±0.4 26.3±0.4 26.4±0.5 
% Body fat 
Men 22.2±0.8 22.3±0.8 25.2±0.8* 
Women 34.7±0.7 34.8±0.7 33.9±0.7 
Sex (%) 
Men 37 43 39 
Women 63 57 61 
Education (y) 15.6±0.1 15.6±0.2 15.6±0.2 
Marital status (%) 
Single 34 32 33 
Married 53 60 55 
Other 13 8 12 
Race (%) 
White 93 93 92 
Black 2 2 4 
Other 5 5 4 
aQ-500 supplement included 500 mg quercetin, 125 mg vitamin C, and 5 mg niacin. 
bQ-1,000 supplement included 1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin. 
*Significantly different than placebo and Q-500 (P<0.025).
Blood Pressure Measurements. Blood pressure was 
measured using an aneroid sphygmomanometer on all 
sub- jects in an overnight fasted state. Subjects rested 
in a seated position with arm supported at heart level 
in a quiet room for 15 minutes before blood pressure 
measurements. At least two measurements were 
obtained until a consistent reading within ±5 mm Hg 
was obtained for both systolic (SBP) and diastolic blood 
pressures (DBP). Mean arterial blood pressure (MAP) 
was calculated using the following equation: 
MAP=DBP+1/3(SBP-DBP). 
Inflammatory Markers. Enzyme-linked immunosorbant as- 
says (R&D Systems, Inc, Minneapolis, MN) were used to 
measure total plasma concentrations of IL-6 (high 
sensitivity), IL-10, granulocyte colony-stimulating factor 
(high sensitivity), monocyte chemoattractant protein 1, 
and tumor necrosis factor-, in accordance with the 
manufacturer protocol, as described in detail elsewhere 
(23). All samples and provided standards were analyzed 
in duplicate. Serum C-reactive protein (high sensitivity) 
was measured using an LX-20 clinical analyzer 
(Beckman, Brea, CA). 
Blood Lipids, Diagnostic Chemistry Panel, Complete Blood Count, 
Leukocyte Differential. Serum total cholesterol, low-density 
lipoprotein  cholesterol,  HDL  cholesterol,  triglycerides, 
glucose, diagnostic chemistries, and a complete blood 
count with leukocyte differential were analyzed in the 
clinical lab of the Watauga Medical Center (Boone, NC) 
using standard clinical laboratory equipment and quality 
standards. Glomerular filtration rate was estimated 
using the Cockcroft & Gault equation (24). 
Statistical  Procedures 
Data were analyzed using a 3 (group)X2 (time) repeated 
measures analysis of variance (ANOVA), between groups 
design, with post hoc analysis using Bonferroni adjusted 
independent t tests that contrasted pre- to post-
supplementation changes of Q-500 and Q-1,000 with 
placebo (P<0.025). When Box’s M suggested that the 
assumptions necessary for the univariate approach were 
not tenable, the multivariate approach to repeated 
measures ANOVA was used (Pillais trace). When 
interaction effects were significant (P:S0.05), post hoc 
analysis was con- ducted using Bonferroni adjusted 
independent t tests that contrasted pre- to post-
supplementation changes of Q-500 and Q-1,000 with 
placebo (P<0.025). Additional repeated measures 
ANOVAs were conducted by adding categorical 
covariates to the model to test for the influence of sex 
(man or woman), BMI (normal <25, over- 
 
 
 
Table 2. Diagnostic chemistry values pre- and post-study for participants in placebo, Q-500a, and Q-1,000b groups 
Interaction 
Variable Placebo (n=335) Q-500 (n=333) Q-1,000 (n=332) P value 
Hemoglobin (g/dL)c
Pre-study 14.9±1.3 14.9±1.4 14.9±1.4 
Post-study 14.8±1.4 14.8±1.3 14.8±1.3 0.999 
Hematocrit (%) 
Pre-study 44.3±3.8 44.6±3.8 44.4±4.0 
Post-study 44.0±3.8 44.1±3.6 44.1±3.7 0.487 
Creatinine (mg/dL)d
Pre-study 0.881±0.161 0.893±0.159 0.877±0.176 
Post-study 0.892±0.160 0.887±0.157* 0.873±0.167* 0.014 
Glomerular filtration ratee (mL/min) 0.006 
Pre-study 104.4±32.8 104.6±33.1 109.2±36.5 
Post-study 103.6±32.4 106.2±33.7* 110.2±36.8* 
Glucose (mg/dL)f
Pre-study 89.3±11.4 89.7±12.6 90.5±17.3 
Post-study 91.1±11.5 91.8±13.8 92.1±17.7 0.751 
aQ-500 supplement included 500 mg quercetin, 125 mg vitamin C, and 5 mg niacin. 
bQ-1,000 supplement included 1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin. 
cTo convert g/dL hemoglobin to g/L, multiply g/dL by 10. To convert g/L hemoglobin to g/dL, multiply g/L by 0.1. Hemoglobin of 14.9 g/dL=149 g/L. 
dTo convert mg/dL creatinine to mol/L, multiply mg/dL by 88.4. To convert mol/L creatinine to mg/dL, multiply mol/L by 0.011. Creatinine of 0.881 mg/dL=78 
mol/L. 
eEstimated glomerular filtration rate (24). 
fTo convert mg/dL glucose to mmol/L, multiply mg/dL by 0.0555. To convert mmol/L glucose to mg/dL, multiply mmol/L by 18.0. Glucose of 89.3 mg/dL=5.0 mmol/L. 
*Significant change from presupplementation compared to placebo (P<0.025).
weight 25 to 29.9, and obese 2:30), and age (<40, 40 to 59, 
and 2:60 years). Subjects reporting current use of choles- 
terol or blood pressure medications were excluded from 
the analysis for lipid profile and MAP, respectively. Data 
are expressed as means±standard error. 
RESULTS 
Table 1 summarizes subject characteristics for those who 
completed this study. Subjects varied widely in age (18 to 
85 years), BMI (16.7 to 52.7), and percent body fat (3.4% 
to 59.5%), and were 60% women and 40% men. No differ- 
ences in any of the characteristics were found between 
groups except the men in the Q-1,000 group had signifi- 
cantly higher body fat percentage compared to those in 
the placebo group (Table 1). Of the 1,023 subjects re- 
cruited into the study, 1,002 completed all phases of the 
study. Among the 21 dropouts (seven from the placebo 
group, six from Q-500, and eight from Q-1,000), 12 failed 
to take the supplement and/or adhere to testing proce- 
dures, and nine reported adverse symptoms from taking 
the supplement. Follow-up revealed no consistent pattern 
of symptoms that could be ascribed to taking the querce- 
tin supplements. Monthly symptom logs revealed no 
group differences over time for gastrointestinal, skin, al- 
lergy, or mental symptoms (data not shown). In addition, 
change in BMI and percent body fat did not differ 
significantly between groups during the 12-week study 
even after adjustment for sex (data not shown). 
Results of blood chemistry measurements are reported 
in Table 2. No significant differences were found for out- 
come measures except for small but significant decreases 
in serum creatinine in the Q-500 and Q-1,000 groups 
compared to placebo, and increases in glomerular filtra- 
tion rate for both Q-500 and Q-1,000 groups compared to 
placebo (Table 2). Hemoglobin and hematocrit also did 
not differ over time. Plasma quercetin increased in a 
dose-responsive manner in both Q-500 and Q-1,000 
groups compared to placebo (interaction effect, P<0.001) 
(Figure). Although there was individual variation in the 
plasma quercetin response to supplementation, increases 
in plasma quercetin were not related to sex, age, or BMI 
(data not shown). 
After excluding subjects on blood pressure medication, 
a small but significant decrease in MAP was measured for 
Q-500 and Q-1,000 compared to placebo (interaction 
P=0.046) and this effect was not related to age, sex, or 
BMI. Table 3 shows that the drop in MAP occurred 
through a combined but nonsignificant reduction in both 
systolic and diastolic blood pressures. 
For all subjects not on cholesterol medication, the pat- 
tern of change in serum total cholesterol over time dif- 
fered in Q-500 compared to placebo (P<0.025), but not 
between Q-1,000 and placebo (Table 4). A significant in- 
teraction effect was measured for low-density lipoprotein 
cholesterol without specific group differences (Table 4). A 
small decrease in HDL cholesterol was measured in the 
Q-1,000 group compared to the placebo group. No signif- 
icant interaction effect was seen for triglycerides. These 
effects did not differ after adjustment for age or sex. After 
covariance with BMI (interaction P value 0.036) the quer- 
cetin-related decrease in total cholesterol was slightly 
larger in those with the highest BMI. 
The pre- to postsupplementation change in plasma IL-6 
for Q-1,000 compared to placebo was statistically differ- 
 
 
 
Figure. Plasma quercetin significantly increased in a dose-dependent manner following 12 weeks of supplementation. *Denotes change from 
pre-study to post-study significantly different from placebo (P<0.001). 
Table 3. Pre- and post-study measurements of systolic, diastolic, and mean arterial blood pressure (BP) for participants receiving placebo, 
Q-500a supplement, or Q-1,000b supplement who were not on blood pressure–lowering medication 
Interaction 
Variable Placebo (n=265) Q-500 (n=271) Q-1,000 (n=257) P value 
Systolic BP (mm Hg) 
Pre-study 118±0.8 118±0.8 117±0.9 
Post-study 117±0.8 115±0.8 115±0.9 0.193 
Diastolic BP (mm Hg) 
Pre-study 75.2±0.5 74.9±0.6 75.3±0.6 
Post-study 75.6±0.5 74.1±0.6 74.5±0.6 0.094 
Mean arterial BP (mm Hg) 
Pre-study 89.5±0.6 89.2±0.6 89.2±0.6 0.046 
Post-study 89.4±0.6 87.8±0.6* 87.9±0.6* 
aQ-500 supplement included 500 mg quercetin, 125 mg vitamin C, and 5 mg niacin. 
bQ-1,000 supplement included 1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin. 
*Pre- to post-study change differed significantly from placebo group (P<0.025).
ent (P<0.025), and this effect was not related to age, sex, 
or BMI. Pre- to post-study changes in serum C-reactive 
protein and plasma cytokines (monocyte chemoattractant 
protein 1, granulocyte colony stimulating factor, IL-10, 
and tumor necrosis factor), did not differ between groups 
(Table 5). 
DISCUSSION 
These data indicate that 12-week supplementation with 
either Q-500 or Q-1,000 increases plasma quercetin levels 
in a dose-responsive manner and is not associated with 
adverse symptoms or detrimental changes in diagnostic 
chemistries. Q-500 or Q-1,000 supplementation did not 
affect plasma markers of inflammation, except for a small 
statistical difference in IL-6 in the Q-1,000 group com- 
pared to placebo. Only small differences were seen in 
lipid measures, including a significant decrease in total 
cholesterol only in the Q-500 group, with a decrease in 
HDL cholesterol in the Q-1,000 group when compared 
with placebo. A small but significant difference in MAP 
was seen in both Q-500 and Q-1,000 groups compared to 
placebo (however, no  difference for SBP or DBP), for 
subjects not taking medication. 
Both the Q-500 and Q-1,000 groups experienced a small 
decrease in serum creatinine and an increase in 
glomerular filtration rate, which led to an increase 
in urine output of approximately 30 mL/day (24). The 
decrease in MAP with quercetin has been reported 
previously in animal models, and increased urine 
output is one proposed mechanism (15). Other 
quercetin-related effects on MAP may be due to a 
down-regulation of kidney epithelial sodium channel 
mRNA expression (thus less sodium re- absorption), and 
increased nitric oxide availability through elevation of 
nitric acid-synthase activity (15,16,25). 
Table 4. Pre- and post-study total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and 
triglyceride levels of participants in the placebo, Q-500a, and Q-1,000b groups who were not on cholesterol-lowering medication 
Interaction 
Variable Placebo (n=288) Q-500 (n=277) Q-1,000 (n=271) P value 
Total cholesterol (mmol/ L)c
Pre-study 5.12±0.06 5.15±0.06 5.04±0.06 0.049 
Post-study 5.10±0.05 5.02±0.06* 4.99±0.06 
LDL cholesterol (mmol/L )c 
Pre-study 2.96±0.05 3.07±0.05 2.94±0.05 0.017 
Post-study 2.83±0.05 2.87±0.05 2.86±0.05 
HDL cholesterol (mmol/L )c 
Pre-study 1.52±0.03 1.44±0.03 1.48±0.03 0.019 
Post-study 1.53±0.03 1.42±0.03 1.45±0.03* 
Triglyceride (mmol/L)d
Pre-study 1.30±0.05 1.30±0.05 1.23±0.05 0.366 
Post-study 1.35±0.08 1.32±0.05 1.27±0.05 
aQ-500 supplement included 500 mg quercetin, 125 mg vitamin C, and 5 mg niacin. 
bQ-1,000 supplement included 1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin. 
cTo convert mmol/L cholesterol to mg/dL, multiply mmol/L by 38.6. To convert mg/dL cholesterol to mmol/L, multiply mg/dL by 0.026. Cholesterol of 5.00 mmol/L=193 
mg/dL. dTo convert mmol/L triglyceride to mg/dL, multiply mmol/L by 88.6. To convert mg/dL triglyceride to mmol/L, multiply mg/dL by 0.0113. Triglyceride of 1.30 
mmol/L=115.2 mg/dL. *Pre- to post-study change differed significantly from placebo group (P<0.025). 
Table 5. Pre- and post-study measurements of inflammatory markers C-reactive protein (CRP), tumor necrosis factor- (TNF), monocyte 
chemoattractant protein 1 (MCP-1), granulocyte colony-stimulating factor (GCSF), interleukin-6 (IL-6), and interleukin-10 (IL-10)a for placebo, 
Q-500b, and Q-1,000c groups 
Interaction 
Variable Placebo (n=312) Q-500 (n=316) Q-1,000 (n=309) P value 
CRP (mg/L)d
Pre-study 3.30±0.25 3.00±0.24 3.12±0.25 
Post-study 3.53±0.27 3.37±0.35 3.07±0.26 0.439 
TNF-o: (pg/mL) 
Pre-study 2.16±0.10 2.05±0.09 1.96±0.08 
Post-study 2.05±0.09 1.95±0.08 1.91±0.07 0.542 
MCP-1 (pg/mL) 
Pre-study 167±3.1 165±3.0 168±3.0 
Post-study 165±2.8 165±2.9 163±3.0 0.311 
GCSF (pg/mL) 
Pre-study 31.5±0.8 31.2±0.8 31.3±0.8 
Post-study 32.6±0.81 31.4±0.8 32.4±0.8 0.654 
IL-6 (pg/mL) 
Pre-study 1.72±0.07 1.68±0.07 1.88±0.08 
Post-study 1.90±0.07 1.91±0.08 1.87±0.08* 0.021 
IL-10 (pg/mL) (n=160) (n=167) (n=166) 
Pre-study 1.85±0.14 1.68±0.09 1.93±0.26 
Post-study 1.91±0.14 1.80±0.19 2.03±0.34 0.864 
aOnly measured in subgroup of subjects. 
bQ-500 supplement included 500 mg quercetin, 125 mg vitamin C, and 5 mg niacin. 
cQ-1,000 supplement included 1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin. 
dTo convert mg/L CRP to nmol/L, multiply mg/L by 9.524. To convert nmol/L CRP to mg/L, multiply nmol/L by 0.105. CRP of 3.30 mg/L=31.43 nmol/L. 
*Pre- to post-study change differed significantly from placebo group (P<0.025).
Two of three previous studies (18,20,21) with human 
subjects also report changes in blood pressure measures 
following quercetin supplementation. A modest reduction 
in blood pressure was found among mildly hypertensive 
subjects (N=22) after 28 days of 730 mg quercetin daily 
(21). Egert and colleagues (19) found a drop in MAP of 0.5 
mm Hg in overweight subjects (aged 25 to 65 years). The 
drop in MAP observed in our study was slightly greater 
than observed by Egert and colleagues, possibly due to 
the supplementation dosing regimen and population 
differences. Egert and colleagues (19) speculated that 
improved endothelial function was the underlying 
mechanism explaining the quercetin related blood 
pressure lowering effect, especially in younger and 
middle-aged individuals. The third human trial was 
unable to mea- sure a blood pressure lowering effect 
among 27 healthy subjects after 28 days of 1,000 mg 
quercetin a day (20). 
A modest decrease in serum cholesterol levels was 
measured in men and women not on cholesterol 
medications in the Q-500 group but not the Q-1,000 group 
compared to placebo. Three previous human trials 
found no effect of short-term quercetin ingestion on 
blood total cholesterol, triglycerides, or low-density 
lipoprotein cholesterol (18- 20). Egert and colleagues 
(19) reported a decrease in HDL cholesterol in 93 
subjects ingesting 150 mg of quercetin/ day for 6 weeks. 
The change in HDL cholesterol following quercetin 
supplementation reported by Egert and col- leagues 
(19) is similar in magnitude to our data. It is noted 
that a decrease in HDL cholesterol is detrimental to 
health. Thus, it appears that high doses of quercetin, in 
our study 1,000 mg/day (when combined with vitamin C 
and niacin), have detrimental effects on HDL cholesterol 
levels in human beings. Contrary to our findings, some 
but not all animal-based studies support improvements 
in the lipid profile following quercetin supplementation 
(12,26-28). Quercetin supplementation significantly 
reduced total cholesterol in rats fed a high-cholesterol 
diet (26), but not when placed on high-fat diets (28). In 
animals, quercetin may decrease serum total cholesterol 
via an increased fecal excretion of cholesterol and bile 
acids through binding and thus inhibition of 
enterohepatic re- circulation  (27,29).  Quercetin  may  
also  decrease  hydroxy-methylglutaryl coenzyme A-
reductase activity in the liver (12). Although the 
mechanism is not clear in humans, the lack of dose 
response in our study indicates higher doses of 
quercetin do not yield better cholesterol lowering 
effects. Interestingly, studies in human beings using 
food products (such as concentrated  grape  juice)  
report  an  improvement  in cholesterol profile(30,31), 
indicating that a mixed fla vonoid approach may be 
more efficient than the one used in this study. 
Q-500 and Q-1,000 supplementation effects on 
inflammation were limited to a small reduction of IL-6 
in the Q-1,000 compared to placebo group, but the 
importance of this finding is weakened due to group 
variance in pre- study IL-6 levels. No effects of Q-500 
or Q-1,000 were measured for C-reactive protein or 
four other cytokines, which is consistent with three 
other studies in human subjects (18,19,32). Egert and 
colleagues. (19) suggested the dose of 150 mg/day was 
too small to elicit an anti- inflammatory effect; 
however, the doses used in our study were substantially 
larger and still did not elicit any significant effect on 
overall inflammatory markers. Quercetin’s anti-
inflammatory effects are evident with in vitro (2,13,32-
34) and animal-based models (13,33). However, the
anti-inflammatory effect of in vivo quercetin conju- 
gates is attenuated (32,35). We recently showed that 
ingestion of quercetin supplements combined with 
other flavonoids, fish oil, and antioxidants decreased 
postexercise inflammation in cyclists following heavy 
exertion 
(23). This finding supports the notion of a mixed flavonoid 
approach to improve the anti-inflammatory effects of 
quercetin. 
CONCLUSIONS 
Supplementation with either Q-500 or Q-1,000 was safe 
but had a negligible influence on disease risk factors. A 
large apple provides 8 to 10 mg quercetin; thus, the 
supplement levels used in this study are not attainable 
through the diet alone. Quercetin was combined with 
vitamin C and niacin into one supplement, and thus it is 
not possible to entirely attribute effects reported in our 
study to quercetin alone. No effects were seen on most 
measures of inflammation. The cholesterol lowering 
effect was small, and limited to the Q-500 group, while 
a decrease in HDL cholesterol was measured in the Q-
1,000 group. The lack of effect of long-term quercetin-
vitamin C-niacin supplementation on the disease risk 
factors measured in this study is in agreement with the 
findings reported by other investigators. Future 
research will determine if the bioactive effects of 
quercetin measured in vitro can be replicated in 
humans by adding other synergistic food components 
such as isoquercetin, green tea extract, fish oil, 
antioxidants, and other types of polyphenols (36-38). 
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